Within regulatory circles, one might argue the biggest trend in recent decades has been the shift toward global harmonization, with a large number of groups launching to help bring about a convergence of good regulatory practices resulting in benefits for both regulators and industry alike. But if a critique is present, it is that the processes by which this harmonization occurs can often be unnecessarily opaque, limiting the input of all but the most well-connected companies and entities.
Now one of the most prominent groups, the International Conference on Harmonisation (ICH), a pharmaceutical regulatory harmonization body consisting of regulators from the US, EU and Japan, is publishing new documents intended to explain in full detail exactly what goes on within its regulatory black box.
ICH first committed to increasing transparency in a June 2013 statement released on its website. The problem, Regulatory Focus noted at the time, is twofold:
The result is something of an opaque organization-far from a positive when its guidelines ultimately affect the pharmaceutical and biopharmaceutical industries of three of the most developed pharmaceutical markets on Earth.
Transparency, then, would stand to benefit industry greatly. And while one part of the ICH's transparency initiative is set to release more detailed information about ongoing ICH activities on a regular basis (including agendas, work plans and working group summaries), the other part of that process has to deal with how ICH functions.
Now ICH is out with a new "Procedure" document intended to explain the entire ICH process from start to finish, most notably including the so-called "5-Step" process.
The extensive 82-page document also includes:
An overview presentation about the procedure document was also made available by ICH on its website.